| Literature DB >> 33152023 |
Jonggi Choi1, So-Hyun Kim1, Seungbong Han2, Danbi Lee1, Ju Hyun Shim1, Young-Suk Lim1, Han Chu Lee1, Young-Hwa Chung1, Yung Sang Lee1, Sung-Gyu Lee3, Ki-Hun Kim3, Kang Mo Kim1.
Abstract
BACKGROUND & AIM: Hepatic resection is a treatment option for patients with hepatocellular carcinoma (HCC). However, factors associated with candidacy for resection and predictive of liver-related morbidity after resection for HCC remain unclear. This study aimed to assess candidacy for liver resection in patients with HCC and to design a model predictive of liver-related morbidity after resection.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33152023 PMCID: PMC7643950 DOI: 10.1371/journal.pone.0241808
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the patients included in this study.
| Characteristics | All (n = 1,565) | Training cohort (n = 1,174) | Validation cohort (n = 391) | |
|---|---|---|---|---|
| Age, years | 58.3 ± 9.9 | 58.4 ± 10.0 | 57.9 ± 9.4 | 0.46 |
| Gender, male/female, n (%) | 1258/307 (80.4/19.6) | 932/242 (79.4/20.6) | 326/65 (83.4/16.6) | 0.10 |
| Etiologies, n (%) | 0.71 | |||
| Alcohol | 101 (6.5) | 24 (6.1) | 77 (6.6) | |
| HBV | 1,265 (80.8) | 325 (83.1) | 940 (80.1) | |
| HCV | 52 (3.3) | 10 (2.6) | 42 (3.6) | |
| HBV + HCV | 9 (0.6) | 2 (0.5) | 7 (0.6) | |
| NBNC | 138 (8.8) | 30 (7.7) | 108 (9.2) | |
| ASA fitness grade, n (%) | 0.15 | |||
| 1 | 30 (1.9) | 7 (1.8) | 23 (2.0) | |
| 2 | 1,385 (88.5) | 335 (85.7) | 1,050 (89.4) | |
| 3 | 146 (9.3) | 48 (12.3) | 98 (8.3) | |
| 4 | 4 (0.3) | 1 (0.3) | 3 (0.3) | |
| Body mass index, kg/m2 | 24.2 ± 3.1 | 24.1 ± 3.0 | 24.2 ± 3.1 | 0.65 |
| Comorbidities, n (%) | ||||
| Diabetes | 314 (20.1) | 76 (19.4) | 238 (20.3) | 0.78 |
| Hypertension | 546 (34.9) | 147 (37.6) | 399 (34.0) | 0.22 |
| Cardiovascular | 19 (1.2) | 5 (1.3) | 14 (1.2) | 0.99 |
| Renal | 13 (0.8) | 3 (0.8) | 10 (0.9) | 0.99 |
| Oncologic | 30 (1.9) | 9 (2.3) | 21 (1.8) | 0.67 |
| Respiratory | 23 (1.5) | 6 (1.5) | 17 (1.4) | 0.99 |
| Cirrhosis, n (%) | 603 (38.5) | 168 (43.0) | 435 (37.1) | 0.60 |
| Varices, n (%) | 13 (0.8) | 1 (0.3) | 12 (1.0) | 0.26 |
| Ascites, n (%) | 1 (0.1) | 0 (0.0) | 1 (0.1) | 0.99 |
| MELD score | 7.7 ± 1.4 | 7.7 ± 1.5 | 7.7 ± 1.4 | 0.73 |
| Child-Pugh score | ||||
| 5 | 1,067 (68.2) | 282 (72.1) | 785 (66.9) | 0.06 |
| 6 | 105 (29.3) | 105 (26.9) | 353 (30.1) | |
| ≥ 7 | 40 (2.6) | 4 (1.0) | 36 (3.0) | |
| Previous TACE, n (%) | 258 (16.5) | 56 (14.3) | 202 (17.2) | 0.21 |
| Previous PVE, n (%) | 156 (10.0) | 38 (9.7) | 118 (10.1) | 0.93 |
| Baseline laboratory exam | ||||
| Hemoglobin, g/dL | 13.6 ± 1.6 | 13.7 ± 1.7 | 13.6 ± 1.6 | 0.09 |
| Platelets, ×1,000/mm3 | 178.2 ± 73.8 | 177.9 ± 84.1 | 178.3 ± 70.0 | 0.93 |
| Prothrombin time, INR | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 | 0.90 |
| Creatinine, mg/dL | 0.9 ± 0.4 | 0.9 ± 0.6 | 0.9 ± 0.3 | 0.23 |
| Albumin, g/dL | 3.7 ± 0.4 | 3.7 ± 0.4 | 3.7 ± 0.4 | 0.43 |
| AST, IU/L | 37.8 ± 31.8 | 37.6 ± 32.3 | 37.8 ± 31.6 | 0.90 |
| ALT, IU/L | 35.0 ± 36.4 | 35.5 ± 33.8 | 34.9 ± 37.3 | 0.77 |
| Total bilirubin, mg/dL | 0.6 ± 0.4 | 0.6 ± 0.3 | 0.7 ± 0.4 | 0.11 |
| Sodium, mmol/L | 139.9 ± 2.5 | 140.0 ± 2.5 | 139.9 ± 2.5 | 0.44 |
| Estimated GFR | 92.7 ± 15.4 | 92.9 ± 16.0 | 92.7 ± 15.2 | 0.80 |
| AFP, ng/mL, median [IQR] | 10.8 [3.6–177.7] | 12.2 [3.9–171.0] | 10.6 [3.5–187.4] | 0.73 |
| ICG R15, median [IQR] | 13.2 [10.3–16.6] | 12.8 [10.3–16.8] | 13.2 [10.2–16.6] | 0.77 |
| Operation | ||||
| Anesthesia time, min, median [IQR] | 245 [210–300] | 245 [210–300] | 246 [210–300] | 0.73 |
| Operation time, min, median [IQR] | 211 [175–263] | 208 [171–262] | 212 [177–263] | 0.29 |
Abbreviations: AFP: alpha-fetoprotein, ALT: alanine aminotransferase, ASA: American Society of Anesthesiologists, AST: aspartate aminotransferase, GFR: glomerular filtration rate, HBV: hepatitis B virus, HCV: hepatitis C virus, ICG: indocyanine green, INR: international normalized ratio, IQR: interquartile range, NBNC: non-HBV and non-HCV, PVE: portal vein embolization, TACE: transarterial chemoembolization
Morbidity and mortality rates after liver resection for hepatocellular carcinoma.
| Morbidities | All (n = 1,565) | Major resection (n = 646) | Minor resection (n = 919) | |
|---|---|---|---|---|
| Liver-related morbidities | 133 (8.5%) | 77 (11.9%) | 56 (6.1%) | < 0.001 |
| INR ≥ 1.5 on or after POD 5 | 48 (3.1) | 33 (5.3) | 15 (1.8) | < 0.001 |
| Total bilirubin ≥ 2.9 mg/dL on or after POD 5 | 49 (3.1) | 29 (4.6) | 20 (2.3) | 0.02 |
| INR ≥ 1.5 or total bilirubin ≥ 2.9 mg/dL on or after POD 5 | 80 (5.1) | 50 (8.0) | 30 (3.5) | < 0.001 |
| Ascites | 51 (3.3) | 26 (4.0) | 25 (2.7) | 0.20 |
| Encephalopathy | 1 (0.1) | 0 (0.0) | 1 (0.1) | 0.99 |
| Liver transplantation due to liver failure | 2 (0.1) | 1 (0.2) | 1 (0.1) | 0.99 |
| Mortality at 30 days | 4 (0.3) | 2 (0.3) | 2 (0.2) | 0.99 |
| Mortality at 90 days | 13 (0.8) | 9 (1.4) | 4 (0.4) | 0.08 |
| Medical morbidities | ||||
| ICU stay/mechanical ventilation | 20 (1.3) | 10 (1.5) | 10 (1.1) | 0.57 |
| Sepsis/bacteremia | 14 (0.9) | 4 (0.6) | 10 (1.1) | 0.49 |
| Pneumonia | 7 (0.4) | 2 (0.3) | 5 (0.5) | 0.76 |
| Renal failure | 3 (0.2) | 1 (0.2) | 2 (0.2) | 0.99 |
| Cardiovascular | 3 (0.2) | 1 (0.2) | 2 (0.2) | 0.99 |
| Neurologic | 4 (0.3) | 2 (0.3) | 2 (0.2) | 0.99 |
| Surgery-related morbidities | ||||
| Bleeding | 7 (0.4) | 4 (0.6) | 3 (0.3) | 0.64 |
| Wound complications | 47 (3.0) | 20 (3.1) | 27 (2.9) | 0.98 |
| Bile leak/perihepatic abscess | 12 (0.8) | 3 (0.5) | 9 (1.0) | 0.64 |
| Fluid collection | 60 (3.8) | 31 (4.8) | 29 (3.2) | 0.13 |
| Portal vein thrombosis | 14 (0.9) | 7 (1.1) | 7 (0.8) | 0.69 |
| Pneumothorax | 4 (0.3) | 3 (0.3) | 9 (1.0) | 0.39 |
| Any post-hepatectomy morbidity | 206 (13.2) | 89 (13.8) | 95 (10.3) | 0.045 |
| Length of hospital stay, days | 13 [11–16] | 13 [11–17] | 12 [10–16] | 0.003 |
| Length of hospital stay after resection, days | 10 [9–12] | 10 [9–12] | 10 [9–12] | 0.003 |
*Greater than on the previous day. Abbreviations: ICU: intensive care unit, INR: international normalized ratio, POD: postoperative day
Fig 1Forest plot of the results of multivariable analysis of factors independently associated with liver-related morbidity after liver resection for hepatocellular carcinoma.
Regression coefficient and odds ratio estimation from the training cohort and the corresponding risk scores.
| OR (95% CI) | B coefficient | Risk score | ||
|---|---|---|---|---|
| Sex | ||||
| Female | 1.00 | 0 | ||
| Male | 1.70 (0.93–3.10) | 0.5298 | 0.085 | 1 |
| Age, years | ||||
| < 55 | 1.00 | 0 | ||
| ≥ 55 | 1.50 (0.94–2.37) | 0.4030 | 0.087 | 1 |
| Type of resection planned | ||||
| Minor | 1.00 | 0 | ||
| Major | 2.24 (1.45–3.46) | 0.8061 | 0.0003 | 2 |
| Platelets, ×1000/mm3 | ||||
| ≥ 150 | 1.00 | 0 | ||
| < 150 | 1.84 (1.20–2.83) | 0.6099 | 0.005 | 2 |
| Serum albumin, g/dL | ||||
| ≥ 3.5 | 1.00 | 0 | ||
| < 3.5 | 1.89 (1.21–2.95) | 0.6382 | 0.005 | 2 |
| Prothrombin time, INR | ||||
| ≤ 1.1 | 1.00 | 0 | ||
| > 1.1 | 2.67 (1.73–4.12) | 0.9804 | < 0.001 | 2 |
| ICG R15 | ||||
| < 15% | 1.00 | 0 | ||
| ≥ 15% | 1.55 (1.00–2.39) | 0.4371 | 0.048 | 1 |
*Abbreviations: ICG: indocyanine green, INR: international normalized ratio, OR: odds ratio
Fig 2Calculated risk of post-hepatectomy liver-related morbidity as a function of risk score.
Cumulative risk scores and corresponding risks of developing post-hepatectomy liver-related morbidity in patients who underwent liver resection for hepatocellular carcinoma.
| Score group | Range of estimated risk | Score | Estimated risk |
|---|---|---|---|
| Low 0 − 2 | 1 − 2% | 0 | 1.1% |
| 1 | 1.6% | ||
| 2 | 2.4% | ||
| Intermediate 3–5 | 3 − 7% | 3 | 3.5% |
| 4 | 5.1% | ||
| 5 | 7.4% | ||
| High 6–8 | 11 − 21% | 6 | 10.7% |
| 7 | 15.2% | ||
| 8 | 21.1% | ||
| Very high 9 − 11 | 29 − 47% | 9 | 28.5% |
| 10 | 37.2% | ||
| 11 | 46.7% |
Fig 3Receiver operating characteristic curves and calibration charts of the training and test cohorts.
A. Receiver operating characteristic curve of the training cohort. B. Receiver operating characteristic curve of the test cohort. C. Calibration chart of the predicted versus observed risk of the training cohort. D. Calibration chart of the predicted versus observed risk of the test cohort.
Representative scoring of risk factors in the model for a patient.
| Score calculation | ||
|---|---|---|
| Risk factor | Value | Score |
| Sex | Male | 1 |
| Age | 56 years | 1 |
| Type of resection planned | Major resection | 2 |
| Platelets | 160,000/mm3 | 0 |
| Serum albumin | 3.7 g/dL | 0 |
| Prothrombin time | 1.05 | 0 |
| ICG R15 | 16% | 1 |
| Total score | 5 | |
| Score group | Intermediate | |
| Estimated risk | 7.4% | |